November 2024 in “International Journal of Scientific Reports” This meta-analysis found that while both Dienogest and GnRH analogues effectively managed endometriosis-related pain, Dienogest reduced recurrence rates and hot flushes but increased irregular bleeding, making it a safer option due to fewer side effects.
January 2026 in “International Journal of Women s Health” This study found that a nomogram prediction model based on clinical characteristics, bone metabolism, and ovarian function can effectively predict the treatment response to long-acting GnRHa in girls with idiopathic central precocious puberty.
4 citations
,
January 1991 in “Journal of dermatological treatment” This study found that GnRH-A treatment significantly reduced hirsuties scores in women with mild idiopathic hirsuties but did not affect hair growth rate or diameter.
4 citations
,
November 2018 in “Endocrinology, Diabetes & Metabolism Case Reports” This report describes two cases of postmenopausal hyperandrogenism where GnRH analogue use suggested an ovarian source of excess androgens, leading to a diagnosis of benign ovarian tumors.
1 citations
,
September 2023 in “JCEM case reports” This case series observed the efficacy of GnRH analogues in diagnosing and treating various forms of ovarian hyperandrogenism, illustrating their role in symptom management without surgery, particularly for benign conditions and refractory androgen excess.
33 citations
,
April 2015 in “Cochrane library” This review examined various treatments for hirsutism and found low to very low quality evidence suggesting that flutamide and spironolactone may help reduce hair growth, while metformin was ineffective.
11 citations
,
May 2003 in “Obstetrics and gynecology (New York. 1953. Online)/Obstetrics and gynecology” This review explores the evaluation and treatment of hirsutism, emphasizing a systematic approach to uncovering its causes and recommending combination therapies for effective management, but presents no new results.
1 citations
,
November 2007 in “Neuro-chirurgie/Neurochirurgie” This study found that cyproterone acetate treatment in late-pubertal trans-girls was safe, well-tolerated, and induced mild feminizing changes, with more pronounced effects when combined with estrogens.
This paper addresses diagnostic criteria and treatment options for polycystic ovary syndrome, emphasizing lifestyle changes and combination oral contraceptives as primary management strategies, but it reports no new clinical results.
July 2008 in “International journal of psychophysiology” This retrospective study found that cyproterone acetate, both alone and with estrogens, was safe, well tolerated, and induced modest feminizing effects in late-pubertal transgender female adolescents.
November 2007 in “Neuro-chirurgie/Neurochirurgie” This study reported that treatment with cyproterone acetate alone and then with incremental estrogen doses induced mild feminizing effects in late-pubertal trans-girls, with further feminization observed after adding estrogen.
Different drugs are used to manage breeding, prevent or end pregnancy, and treat reproductive issues in dogs and cats.
42 citations
,
September 2007 in “The Journal of Clinical Endocrinology and Metabolism” This study found that women with PCOS who have an exaggerated 17-hydroxyprogesterone response to buserelin exhibit more severe hyperandrogenemia, increased insulin secretion, and reduced insulin sensitivity.
82 citations
,
February 1989 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” This study found that in men with benign prostatic hyperplasia, a 3-month treatment with a long-acting GnRH agonist significantly reduced intraprostatic DHT and 3α-diol levels by about 90% and testosterone by about 75%.
2 citations
,
December 1994 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” This study concluded that a regimen of transdermal estradiol and oral medroxyprogesterone acetate effectively reduces hirsutism while minimizing side effects in women with polycystic ovary syndrome.
36 citations
,
May 2011 in “The Journal of Clinical Endocrinology & Metabolism” Treatment with a hormone agonist can reduce excess male hormones in postmenopausal women without surgery.
September 2014 in “Springer eBooks” This review discusses the evaluation and management of breast pain, or mastalgia, highlighting non-pharmacologic therapies and the limited role of surgical interventions, but reports no new clinical findings.
January 2024 in “Frontiers in endocrinology” This study found that women treated with GnRHa for central precocious puberty had a higher prevalence of polycystic ovary syndrome in adulthood compared to those with isolated premature thelarche.
2 citations
,
February 2021 in “Brain Research” This study found that testosterone replacement in castrated male rats counteracted endotoxemia-induced arterial baroreflex dysfunction without significantly affecting neuroinflammation.
May 2026 in “Journal of Assisted Reproduction and Genetics” In this study, researchers developed and tested a novel peptide, AMHR2BP, which mimics the function of Anti-Müllerian hormone to protect ovarian follicles in mice, showing promise for preserving ovarian health during chemotherapy without causing toxicity.
32 citations
,
November 1996 in “International Journal of Dermatology” This review discusses the use of antiandrogen therapy in dermatology, covering treatments for conditions like acne, hirsutism, and androgenic alopecia but reports no new clinical findings.
70 citations
,
March 2016 in “Urologic Clinics of North America” This article reviews the coordination of the hypothalamic-pituitary-gonadal axis, male fertility, and therapies for hypogonadism, but reports no new clinical findings.
May 2021 in “Journal of the Endocrine Society” This case report details a diagnosis of adult-onset isolated hypogonadotropic hypogonadism in a 23-year-old African American female, highlighting its genetic basis and treatment approach.
46 citations
,
September 2016 in “Clinical, Cosmetic and Investigational Dermatology” This article reviews the hormonal pathogenesis and treatment strategies for acne vulgaris, particularly in women with severe or treatment-resistant cases, associating it with hormonal imbalances and hyperandrogenism.
15 citations
,
August 1998 in “Australasian journal of dermatology” This review discusses various treatments for hirsutism, including cosmetic techniques, anti-androgens like spironolactone, and new drugs such as finasteride and flutamide, but it reports no new clinical results.
39 citations
,
May 2011 in “European Journal of Clinical Investigation” This review discusses the various causes of hirsutism other than PCOS, emphasizing the importance of distinguishing potentially life-threatening conditions like androgen-secreting tumors from more benign causes; it reports no new clinical findings.
November 2010 in “Clin-Alert” Monitoring for adverse effects in clinical treatments is crucial.
30 citations
,
June 1988 in “Journal of Steroid Biochemistry” This study found that combining Flutamide and an LHRH agonist in adult male rats effectively inhibited prostatic growth and reduced androgen-sensitive prostatic activity markers to levels similar to castrated rats.
8 citations
,
February 2021 in “Journal of the American Heart Association” This study observed that medical castration for prostate cancer prolongs the QT/QTc intervals, potentially leading to serious arrhythmias like torsade de pointes and ventricular fibrillation, even in patients without prior QT prolongation risk.
1 citations
,
September 2024 in “Journal of Clinical & Translational Endocrinology” This study found that women with polycystic ovary syndrome have more pronounced metabolic alterations and higher androgen levels compared to women with eumenorrheic hyperandrogenism, suggesting EuHyperA may be a milder form of PCOS.